Leptomeningeal Metastasis

Current Problems in Cancer

Volumn 31, Issue 6, 2007, Pages 372-424

  O'Meara, William P ^a   Borkar, Sunita A ^b   Stambuk, Hilda E ^b   Lymberis, Stella C ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANALGESIC AGENT; ANTICONVULSIVE AGENT; CORTICOSTEROID; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GEMCITABINE; INTERLEUKIN 2; IODINE 131; MAFOSFAMIDE; MELPHALAN; METHOTREXATE; NITROSOUREA; PENTETATE INDIUM IN 113M; PENTETATE TECHNETIUM TC 99M; RITUXIMAB; TAMOXIFEN; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN; TRASTUZUMAB; TUMOR MARKER;

AMNION FLUID CYTOLOGY; ARACHNOIDITIS; AREFLEXIA; ARTICLE; BABINSKI REFLEX; BONE MARROW SUPPRESSION; BRAIN RADIATION; BRAIN VENTRICLE PERITONEUM SHUNT; BREAST CANCER; BURKITT LYMPHOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUDA EQUINA SYNDROME; CEREBROSPINAL FLUID; CHRONIC FATIGUE SYNDROME; CISTERNA MAGNA; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CRANIAL NERVE; DELIRIUM; DIABETES INSIPIDUS; DIAGNOSTIC ACCURACY; DIPLOPIA; DISEASE ACTIVITY; DRUG WITHDRAWAL; DYSARTHRIA; DYSPHAGIA; EDEMA; EXTERNAL BEAM RADIOTHERAPY; FACIAL NERVE PARALYSIS; GAIT DISORDER; HEADACHE; HEARING LOSS; HEMISPHERE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HYDROCEPHALUS; HYPOGLOSSAL NERVE DISEASE; INTRACRANIAL HYPERTENSION; LEPTOMENINX; LEUKOENCEPHALOPATHY; LUNG CANCER; MELANOMA; MENINGEAL METASTASIS; MENTAL DEFICIENCY; MENTAL DISEASE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NERVE FIBER; NEUROIMAGING; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOPLEGIA; OPTIC NERVE DISEASE; PAPILLEDEMA; PATHOPHYSIOLOGY; PROGNOSIS; RADICULAR PAIN; REFLEX DISORDER; RISK FACTOR; SEIZURE; SENSORY DYSFUNCTION; SPINE; TRIGEMINUS NEURALGIA; UNCONSCIOUSNESS; VISUAL IMPAIRMENT; VOMITING; WEAKNESS; BIOLOGICAL MODEL; MENINGIOMA; MENINX; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIOGRAPHY; REVIEW; SCINTISCANNING; TREATMENT OUTCOME;

COMBINED MODALITY THERAPY; HUMANS; MENINGEAL NEOPLASMS; MENINGES; MODELS, BIOLOGICAL; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 36248944622     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2007.07.001     Document Type: Article

References (213)

1. Posner J.B. Neurologic Complications of Cancer (1995), F.A. Davis Company, Philadelphia, PA
2. Aisner J., Aisner S.C., Ostrow S., Govindan S., Mummert K., and Wiernik P. Meningeal carcinomatosis from small cell carcinoma of the lung. Consequence of improved survival. Acta Cytol 23 4 (1979) 292-299
3. Aroney R.S., Dalley D.N., Chan W.K., Bell D.R., and Levi J.A. Meningeal carcinomatosis in small cell carcinoma of the lung. Am J Med 71 1 (1981) 26-32
4. Freilich R.J., Seidman A.D., and DeAngelis L.M. Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Cancer 76 2 (1995) 232-236
5. Gasecki A.P., Bashir R.M., and Foley J. Leptomeningeal carcinomatosis: a report of 3 cases and review of the literature. Eur Neurol 32 2 (1992) 74-78
6. Johnson J.D., and Young B. Demographics of brain metastasis. Neurosurg Clin North Am 7 3 (1996) 337-344
7. Nugent J.L., Bunn Jr. P.A., Matthews M.J., et al. CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival. Cancer 44 5 (1979) 1885-1893
8. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 2 (2006) 106-130
9. Kosmas C., Malamos N.A., Tsavaris N.B., et al. Isolated leptomeningeal carcinomatosis (carcinomatous meningitis) after taxane-induced major remission in patients with advanced breast cancer. Oncology 63 1 (2002) 6-15
10. Kosmas C., Malamos N.A., Tsavaris N.B., et al. Leptomeningeal carcinomatosis after major remission to taxane-based front-line therapy in patients with advanced breast cancer. J Neurooncol 56 3 (2002) 265-273
11. Rosen S.T., Aisner J., Makuch R.W., et al. Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review of the National Cancer Institute experience. Medicine (Baltimore) 61 1 (1982) 45-53
12. Boogerd W., Hart A.A., van der Sande J.J., and Engelsman E. Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 67 6 (1991) 1685-1695
13. Yap H.Y., Yap B.S., Tashima C.K., DiStefano A., and Blumenschein G.R. Meningeal carcinomatosis in breast cancer. Cancer 42 1 (1978) 283-286
14. Chamberlain M.C. Neoplastic meningitis. Neurologist 12 4 (2006) 179-187
15. Chamberlain M.C. Carcinomatous meningitis. Arch Neurol 54 1 (1997) 16-17
16. Jayson G.C., and Howell A. Carcinomatous meningitis in solid tumours. Ann Oncol 7 8 (1996) 773-786
17. Grossman S.A., and Krabak M.J. Leptomeningeal carcinomatosis. Cancer Treat Rev 25 2 (1999) 103-119
18. Chamberlain M.C., Nolan C., and Abrey L.E. Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. J Neurooncol 75 1 (2005) 71-83
19. DeAngelis L.M., and Boutros D. Leptomeningeal metastasis. Cancer Invest 23 2 (2005) 145-154
20. Groves M.D. The pathogenesis of neoplastic meningitis. Curr Oncol Rep 5 1 (2003) 15-23
21. Seute T., Leffers P., ten Velde G.P., and Twijnstra A. Leptomeningeal metastases from small cell lung carcinoma. Cancer 104 8 (2005) 1700-1705
22. Kesari S., and Batchelor T.T. Leptomeningeal metastases. Neurol Clin 21 1 (2003) 25-66
23. Posner J.B., and Chernik N.L. Intracranial metastases from systemic cancer. Adv Neurol 19 (1978) 579-592
24. Balm M., and Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol 53 7 (1996) 626-632
25. Wasserstrom W.R., Glass J.P., and Posner J.B. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49 4 (1982) 759-772
26. Fuchs I.B., Loebbecke M., Buhler H., et al. HER2 in brain metastases: issues of concordance, survival, and treatment. J Clin Oncol 20 19 (2002) 4130-4133
27. Swirsky D.M., Li Y.S., Matthews J.G., Flemans R.J., Rees J.K., and Hayhoe F.G. 8;21 translocation in acute granulocytic leukaemia: cytological, cytochemical and clinical features. Br J Haematol 56 2 (1984) 199-213
28. Holmes R., Keating M.J., Cork A., et al. A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22). Blood 65 5 (1985) 1071-1078
29. Glass J.P., Van Tassel P., Keating M.J., Cork A., Trujillo J., and Holmes R. Central nervous system complications of a newly recognized subtype of leukemia: AMML with a pericentric inversion of chromosome 16. Neurology 37 4 (1987) 639-644
30. Hagemeijer A., Hahlen K., Sizoo W., and Abels J. Translocation (9;11)(p21;q23) in three cases of acute monoblastic leukemia. Cancer Genet Cytogenet 5 2 (1982) 95-105
31. Wong E.T., and O'Brien S. Leptomeningeal disease in pre-leukemic syndrome: cytogenetic abnormality versus cellular morphology. Oncol Rep 5 2 (1998) 493-495
32. Barshes N., Demopoulos A., and Engelhard H.H. Anatomy and physiology of the leptomeninges and CSF space. Cancer Treat Res 125 (2005) 1-16
33. Esiri M.M., and Gay D. Immunological and neuropathological significance of the Virchow-Robin space. J Neurol Sci 100 1-2 (1990) 3-8
34. Sanan A., and van Loveren H.R. The arachnoid and the myth of Arachne. Neurosurgery 45 1 (1999) 152-155
35. Moore K.L., and Dalley A.F. Clinically Oriented Anatomy. (4th ed) (1999), Lippincott Williams & Wilkins, Philadelphia, PA
36. Garton H.J., and Piatt Jr. J.H. Hydrocephalus. Pediatr Clin North Am 51 2 (2004) 305-325
37. Wolpow E.R., and Schaumburg H.H. Structure of the human arachnoid granulation. J Neurosurg 37 6 (1972) 724-727
38. Milhorat T.H. The third circulation revisited. J Neurosurg 42 6 (1975) 628-645
39. Yasargil M.G., Kasdaglis K., Jain K.K., and Weber H.P. Anatomical observations of the subarachnoid cisterns of the brain during surgery. J Neurosurg 44 3 (1976) 298-302
40. Rogers L.R., Duchesneau P.M., Nunez C., et al. Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis. Neurology 42 6 (1992) 1239-1241
41. Kokkoris C.P. Leptomeningeal carcinomatosis. How does cancer reach the pia-arachnoid?. Cancer 51 1 (1983) 154-160
42. Olson M.E., Chernik N.L., and Posner J.B. Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. Arch Neurol 30 2 (1974) 122-137
43. Price R.A., and Johnson W.W. The central nervous system in childhood leukemia. I. The arachnoid. Cancer 31 3 (1973) 520-533
44. Hayat G., Ehsan T., Selhorst J.B., and Manepali A. Magnetic resonance evidence of perineural metastasis. J Neuroimaging 5 2 (1995) 122-125
45. Redman B.G., Tapazoglou E., and Al-Sarraf M. Meningeal carcinomatosis in head and neck cancer. Report of six cases and review of the literature. Cancer 58 12 (1986) 2656-2661
46. Norris L.K., Grossman S.A., and Olivi A. Neoplastic meningitis following surgical resection of isolated cerebellar metastasis: a potentially preventable complication. J Neurooncol 32 3 (1997) 215-223
47. van der Ree T.C., Dippel D.W., Avezaat C.J., Sillevis Smitt P.A., Vecht C.J., and van den Bent M.J. Leptomeningeal metastasis after surgical resection of brain metastases. J Neurol Neurosurg Psychiatry 66 2 (1999) 225-227
48. Siomin V.E., Vogelbaum M.A., Kanner A.A., Lee S.Y., Suh J.H., and Barnett G.H. Posterior fossa metastases: risk of leptomeningeal disease when treated with stereotactic radiosurgery compared to surgery. J Neurooncol 67 1-2 (2004) 115-121
49. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 3 7 (2003) 643-651
50. Nathoo N., Chahlavi A., Barnett G.H., and Toms S.A. Pathobiology of brain metastases. J Clin Pathol 58 3 (2005) 237-242
51. Jaeckle K.A. Neoplastic meningitis from systemic malignancies: diagnosis, prognosis and treatment. Semin Oncol 33 3 (2006) 312-323
52. Amer M.H., Al-Sarraf M., Baker L.H., and Vaitkevicius V.K. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 42 2 (1978) 660-668
53. Houck W.A., Olson K.B., and Horton J. Clinical features of tumor metastasis to the pituitary. Cancer 26 3 (1970) 656-659
54. Yap H.Y., Tashima C.K., Blumenschein G.R., and Eckles N. Diabetes insipidus and breast cancer. Arch Intern Med 139 9 (1979) 1009-1011
55. Crawford N.P., and Hunter K.W. New perspectives on hereditary influences in metastatic progression. Trends Genet 22 10 (2006) 555-561
56. Minn A.J., Gupta G.P., Siegel P.M., et al. Genes that mediate breast cancer metastasis to lung. Nature 436 7050 (2005) 518-524
57. Minn A.J., Kang Y., Serganova I., et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 115 1 (2005) 44-55
58. Steeg P.S. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12 8 (2006) 895-904
59. Kaplan J.G., DeSouza T.G., Farkash A., et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 9 3 (1990) 225-229
60. Zucca E., Conconi A., Mughal T.I., et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 21 1 (2003) 20-27
61. Al-Abbadi M.A., Hattab E.M., Tarawneh M.S., Amr S.S., Orazi A., and Ulbright T.M. Primary testicular diffuse large B-cell lymphoma belongs to the nongerminal center B-cell-like subgroup: a study of 18 cases. Mod Pathol 19 12 (2006) 1521-1527
62. X Practice Guidelines in Central Nervous System Cancers (2006). http://www.nccn.org Available from: http://www.nccn.org. Accessed December 12, 2006
63. Hansen K., Gjerris F., and Sorensen P.S. Absence of hydrocephalus in spite of impaired cerebrospinal fluid absorption and severe intracranial hypertension. Acta Neurochir (Wien) 86 3-4 (1987) 93-97
64. Demopoulos A., and Posner J.B. Pathophysiology and clinical features of leptomeingeal metastases (carcinomatous meningitis). UpToDate (2006) Waltham, MA
65. Broderick J.P., and Cascino T.L. Nonconvulsive status epilepticus in a patient with leptomeningeal cancer. Mayo Clin Proc 62 9 (1987) 835-837
66. Straathof C.S., de Bruin H.G., Dippel D.W., and Vecht C.J. The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis. J Neurol 246 9 (1999) 810-814
67. Chamberlain M.C., Sandy A.D., and Press G.A. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 40 3 Pt 1 (1990) 435-438
68. Freilich R.J., Krol G., and DeAngelis L.M. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 38 1 (1995) 51-57
69. Jaeckle K.A. Assessment of tumor markers in cerebrospinal fluid. Clin Lab Med 5 2 (1985) 303-315
70. Collie D.A., Brush J.P., Lammie G.A., et al. Imaging features of leptomeningeal metastases. Clin Radiol 54 11 (1999) 765-771
71. Rodesch G., Van Bogaert P., Mavroudakis N., et al. Neuroradiologic findings in leptomeningeal carcinomatosis: the value interest of gadolinium-enhanced MRI. Neuroradiology 32 1 (1990) 26-32
72. Fukui M.B., Meltzer C.C., Kanal E., and Smirniotopoulos J.G. MR imaging of the meninges. Part II. Neoplastic disease. Radiology 201 3 (1996) 605-612
73. Glass J.P., Melamed M., Chernik N.L., and Posner J.B. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 29 10 (1979) 1369-1375
74. Glantz M.J., Cole B.F., Glantz L.K., et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 82 4 (1998) 733-739
75. Chamberlain M.C., Kormanik P.A., and Glantz M.J. A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. Neurooncol 3 1 (2001) 42-45
76. Adachi N. Beta-2-microglobulin levels in the cerebrospinal fluid: their value as a disease marker. A review of the recent literature. Eur Neurol 31 4 (1991) 181-185
77. Ohta H., Koyama R., Nagai T., Hirayama Y., Saito S., and Yonesaka A. Meningeal carcinomatosis from an ovarian primary with complete response to adjuvant chemotherapy after cranial irradiation. Int J Clin Oncol 6 3 (2001) 157-162
78. Machado A.B., Machado A.A., Barbuto J.A., and de Oliveira R.M. Central nervous system metastases from breast carcinoma. A clinical and laboratorial study in 47 patients. Ar Qneuropsiquiatr 56 2 (1998) 188-192
79. Mencel P.J., DeAngelis L.M., and Motzer R.J. Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma. Cancer 73 7 (1994) 1892-1894
80. Klee G.G., Tallman R.D., Goellner J.R., and Yanagihara T. Elevation of carcinoembryonic antigen in cerebrospinal fluid among patients with meningeal carcinomatosis. Mayo Clin Proc 61 1 (1986) 9-13
81. Shuttleworth E., and Allen N. CSF beta-glucuronidase assay in the diagnosis of neoplastic meningitis. Arch Neurol 37 11 (1980) 684-687
82. Twijnstra A., Ongerboer de Visser B.W., and van Zanten A.P. Diagnosis of leptomeningeal metastasis. Clin Neurol Neurosurg 89 2 (1987) 79-85
83. Fleisher M., Wasserstrom W.R., Schold S.C., Schwartz M.K., and Posner J.B. Lactic dehydrogenase isoenzymes in the cerebrospinal fluid of patients with systemic cancer. Cancer 47 11 (1981) 2654-2659
84. DeAngelis L.M., and Posner J.B. Telomerase activity in brain and leptomeningeal metastases. J Neurol Sci 161 2 (1998) 114-115
85. Kleinschmidt-DeMasters B.K., Evans L.C., Bitter M.A., Shroyer A.L., and Shroyer K.R. Part II. Telomerase expression in cerebrospinal fluid specimens as an adjunct to cytologic diagnosis. J Neurol Sci 161 2 (1998) 124-134
86. Herrlinger U., Wiendl H., Renninger M., Forschler H., Dichgans J., and Weller M. Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value. Br J Cancer 91 2 (2004) 219-224
87. Stockhammer G., Poewe W., Burgstaller S., et al. Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology 54 8 (2000) 1670-1676
88. Twijnstra A., Ongerboer de Visser B.W., van Zanten A.P., Hart A.A., and Nooyen W.J. Serial lumbar and ventricular cerebrospinal fluid biochemical marker measurements in patients with leptomeningeal metastases from solid and hematological tumors. J Neurooncol 7 1 (1989) 57-63
89. Cibas E.S., Malkin M.G., Posner J.B., and Melamed M.R. Detection of DNA abnormalities by flow cytometry in cells from cerebrospinal fluid. Am J Clin Pathol 88 5 (1987) 570-577
90. Thomas J.E., Falls E., Velasco M.E., and Zaher A. Diagnostic value of immunocytochemistry in leptomeningeal tumor dissemination. Arch Pathol Lab Med 124 5 (2000) 759-761
91. Gleissner B., Siehl J., Korfel A., Reinhardt R., and Thiel E. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology 58 3 (2002) 390-396
92. Rhodes C.H., Glantz M.J., Glantz L., et al. A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis. Cancer 77 3 (1996) 543-548
93. Storch-Hagenlocher B., Haas J., Vogt-Schaden M.E., et al. Molecular analysis of the CDR3 encoding region of the immunoglobulin heavy chain locus in cerebrospinal fluid cells as a diagnostic tool in lymphomatous meningitis. Ann Neurol 47 2 (2000) 211-217
94. van Oostenbrugge R.J., Hopman A.H., Ramaekers F.C., and Twijnstra A. In situ hybridization: a possible diagnostic aid in leptomeningeal metastasis. J Neurooncol 38 2-3 (1998) 127-133
95. van Oostenbrugge R.J., Hopman A.H., Arends J.W., Ramaekers F.C., and Twijnstra A. Treatment of leptomeningeal metastases evaluated by interphase cytogenetics. J Clin Oncol 18 10 (2000) 2053-2058
96. Karnofsky D.A., Abelmann W.H., Craver L.F., and Burchenal J.H. The use of the nitrogen mustards in the palliative treatment of carcinoma: with particular reference to bronchogenic carcinoma (1948) 634-656
97. Demopoulos A., and Posner J.B. Treatment of leptomeningeal metastases (carcinomatous meningitis). UpToDate (2006) Waltham, MA
98. Greenfield J.P., and Bilsky M.H. Neurosurgical interventions for leptomeningeal tumor. Cancer Treat Res 125 (2005) 107-119
99. Ommaya A.K. Subcutaneous reservoir and pump for sterile access to ventricular cerebrospinal fluid. Lancet 282 7315 (1963) 983-984
100. Shapiro W.R., Young D.F., and Mehta B.M. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 293 4 (1975) 161-166
101. Larson S.M., Schall G.L., and Di Chiro G. The influence of previous lumbar puncture and pneumoencephalography on the incidence of unsuccessful radioisotope cisternography. J Nucl Med 12 8 (1971) 555-557
102. Galicich J.H., and Guido L.J. Ommaya device in carcinomatous and leukemic meningitis: surgical experience in 45 cases. Surg Clin North Am 54 4 (1974) 915-922
103. Lishner M., Perrin R.G., Feld R., et al. Complications associated with Ommaya reservoirs in patients with cancer. The Princess Margaret Hospital experience and a review of the literature. Arch Intern Med 150 1 (1990) 173-176
104. Obbens E.A., Leavens M.E., Beal J.W., and Lee Y.Y. Ommaya reservoirs in 387 cancer patients: a 15-year experience. Neurology 35 9 (1985) 1274-1278
105. Sandberg D.I., Bilsky M.H., Souweidane M.M., Bzdil J., and Gutin P.H. Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 47 1 (2000) 49-54
106. Chamberlain M.C., Kormanik P.A., and Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 87 5 (1997) 694-699
107. Lemann W., Wiley R.G., and Posner J.B. Leukoencephalopathy complicating intraventricular catheters: clinical, radiographic and pathologic study of 10 cases. J Neurooncol 6 1 (1988) 67-74
108. Shapiro W.R., Chernik N.L., and Posner J.B. Necrotizing encephalopathy following intraventricular instillation of methotrexate. Arch Neurol 28 2 (1973) 96-102
109. Grossman S.A., Trump D.L., Chen D.C., Thompson G., and Camargo E.E. Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography. Am J Med 73 5 (1982) 641-647
110. Chamberlain M.C. Pediatric leptomeningeal metastasis: 111In-DTPA cerebrospinal fluid flow studies. J Child Neurol 9 2 (1994) 150-154
111. Chamberlain M.C., and Corey-Bloom J. Leptomeningeal metastases: 111indium-DTPA CSF flow studies. Neurology 41 11 (1991) 1765-1769
112. Chiro G.D., Hammock M.K., and Bleyer W.A. Spinal descent of cerebrospinal fluid in man. Neurology 26 1 (1976) 1-8
113. Haaxma-Reiche H., Piers A., and Beekhuis H. Normal cerebrospinal fluid dynamics. A study with intraventricular injection of 111In-DTPA in leukemia and lymphoma without meningeal involvement. Arch Neurol 46 9 (1989) 997-999
114. Larson S.M., Johnston G.S., Ommaya A.K., Jones A.E., and Di Chiro G. The radionuclide ventriculogram. JAMA 224 6 (1973) 853-857
115. Lyons M.K., and Meyer F.B. Cerebrospinal fluid physiology and the management of increased intracranial pressure. Mayo Clin Proc 65 5 (1990) 684-707
116. Chamberlain M.C. Comparative spine imaging in leptomeningeal metastases. J Neurooncol 23 3 (1995) 233-238
117. Chamberlain M.C. Spinal 111Indium-DTPA CSF flow studies in leptomeningeal metastasis. J Neurooncol 25 2 (1995) 135-141
118. Chamberlain M.C. Radioisotope CSF flow studies in leptomeningeal metastases. J Neurooncol 38 2-3 (1998) 135-140
119. Mason W.P., Yeh S.D., and DeAngelis L.M. 111Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology 50 2 (1998) 438-444
120. Chamberlain M.C., and Kormanik P.A. Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology 46 6 (1996) 1674-1677
121. Glantz M.J., Hall W.A., Cole B.F., et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 75 12 (1995) 2919-2931
122. Mehta M., and Bradley K. Radiation therapy for leptomeningeal cancer. Cancer Treat Res 125 (2005) 147-158
123. Gray J.R., and Wallner K.E. Reversal of cranial nerve dysfunction with radiation therapy in adults with lymphoma and leukemia. Int J Radiat Oncol Biol Phys 19 2 (1990) 439-444
124. Hermann B., Hultenschmidt B., and Sautter-Bihl M.L. Radiotherapy of the neuroaxis for palliative treatment of leptomeningeal carcinomatosis. Strahlenther Onkol 177 4 (2001) 195-199
125. Taillibert S., Laigle-Donadey F., Chodkiewicz C., Sanson M., Hoang-Xuan K., and Delattre J.Y. Leptomeningeal metastases from solid malignancy: a review. J Neurooncol 75 1 (2005) 85-99
126. Bezek S., Trnovec T., Scasnar V., et al. Irradiation of the head by 60Co opens the blood-brain barrier for drugs in rats. Experientia 46 10 (1990) 1017-1020
127. d'Avella D., Cicciarello R., Angileri F.F., Lucerna S., La Torre D., and Tomasello F. Radiation-induced blood-brain barrier changes: pathophysiological mechanisms and clinical implications. Acta Neurochir Suppl 71 (1998) 282-284
128. Delattre J.Y., Shapiro W.R., and Posner J.B. Acute effects of low-dose cranial irradiation on regional capillary permeability in experimental brain tumors. J Neurol Sci 90 2 (1989) 147-153
129. Krueck W.G., Schmiedl U.P., Maravilla K.R., Spence A.M., Starr F.L., and Kenney J. MR assessment of radiation-induced blood-brain barrier permeability changes in rat glioma model. AJNR Am J Neuroradiol 15 4 (1994) 625-632
130. Rubin P., Gash D.M., Hansen J.T., Nelson D.F., and Williams J.P. Disruption of the blood-brain barrier as the primary effect of CNS irradiation. Radiother Oncol 31 1 (1994) 51-60
131. Schultheiss T.E., Kun L.E., Ang K.K., and Stephens L.C. Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys 31 5 (1995) 1093-1112
132. Gajjar A., Chintagumpala M., Ashley D., et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 7 10 (2006) 813-820
133. Packer R.J., Gajjar A., Vezina G., et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24 25 (2006) 4202-4208
134. Chang E.L., and Maor M.H. Standard and novel radiotherapeutic approaches to neoplastic meningitis. Curr Oncol Rep 5 1 (2003) 24-28
135. Bauman G., Wong E., Trenka K., and Scott D. A simple technique for craniospinal radiotherapy in the supine position. Radiother Oncol 80 3 (2006) 394
136. Malik M., Prabhakar R., Sharma D.N., and Rath G.K. Retinoblastoma with cerebrospinal fluid metastasis treated with orbital and craniospinal irradiation using IMRT. Technol Cancer Res Treat 5 5 (2006) 497-501
137. Wilkinson J.M., Lewis J., Lawrence G.P., Lucraft H.H., and Murphy E. Craniospinal irradiation using a forward planned segmented field technique. Br J Radiol 80 951 (2007) 209-215
138. St Clair W.H., Adams J.A., Bues M., et al. Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int J Radiat Oncol Biol Phys 58 3 (2004) 727-734
139. Yuh G.E., Loredo L.N., Yonemoto L.T., et al. Reducing toxicity from craniospinal irradiation: using proton beams to treat medulloblastoma in young children. Cancer J 10 6 (2004) 386-390
140. D'Angio G.J., French L.A., Stadlan E.M., and Kieffer S.A. Intrathecal radioisotopes for the treatment of brain tumors. Clin Neurosurg 15 (1968) 288-300
141. Doge H., and Hliscs R. Intrathecal therapy with 198Au-colloid for meningosis prophylaxis. Eur J Nucl Med 9 3 (1984) 125-128
142. Metz O., Stoll W., and Plenert W. Meningosis prophylaxis with intrathecal 198Au-colloid and methotrexate in childhood acute lymphocytic leukemia. Cancer 49 2 (1982) 224-228
143. Coakham H.B., and Kemshead J.T. Treatment of neoplastic meningitis by targeted radiation using (131)I-radiolabelled monoclonal antibodies. Results of responses and long term follow-up in 40 patients. J Neurooncol 38 2-3 (1998) 225-232
144. Coakham H.B., Richardson R.B., Davies A.G., Bourne S.P., Eckert H., and Kemshead J.T. Neoplastic meningitis from a pineal tumour treated by antibody-guided irradiation via the intrathecal route. Br J Neurosurg 2 2 (1988) 199-209
145. Coakham H.B., Richardson R.B., Davies A.G., et al. Antibody-guided radiation therapy via the CSF for malignant meningitis. Lancet 2 8511 (1986) 860-861
146. Moseley R.P., Davies A.G., Richardson R.B., et al. Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis. Br J Cancer 62 4 (1990) 637-642
147. Hafeli U.O., Sweeney S.M., Beresford B.A., Sim E.H., and Macklis R.M. Magnetically directed poly(lactic acid) 90Y-microspheres: novel agents for targeted intracavitary radiotherapy. J Biomed Mater Res 28 8 (1994) 901-908
148. Glantz M.J., Cole B.F., Recht L., et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?. J Clin Oncol 16 4 (1998) 1561-1567
149. Bleyer W.A., Coccia P.F., Sather H.N., et al. Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. J Clin Oncol 1 5 (1983) 317-325
150. Fleischhack G., Jaehde U., and Bode U. Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clin Pharmacokinet 44 1 (2005) 1-31
151. Glantz M.J., Jaeckle K.A., Chamberlain M.C., et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5 11 (1999) 3394-3402
152. Jaeckle K.A., Batchelor T., O'Day S.J., et al. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol 57 3 (2002) 231-239
153. Jaeckle K.A., Phuphanich S., Bent M.J., et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 84 2 (2001) 157-163
154. Chamberlain M.C., Khatibi S., Kim J.C., Howell S.B., Chatelut E., and Kim S. Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study. Arch Neurol 50 3 (1993) 261-264
155. Cole B.F., Glantz M.J., Jaeckle K.A., Chamberlain M.C., and Mackowiak J.I. Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer 97 12 (2003) 3053-3060
156. Trump D.L., Grossman S.A., Thompson G., Murray K., and Wharam M. Treatment of neoplastic meningitis with intraventricular thiotepa and methotrexate. Cancer Treat Rep 66 7 (1982) 1549-1551
157. Boogerd W., van den Bent M.J., Koehler P.J., et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 40 18 (2004) 2726-2733
158. Siegal T., Lossos A., and Pfeffer M.R. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 44 8 (1994) 1463-1469
159. Herrlinger U., Forschler H., Kuker W., et al. Leptomeningeal metastasis: survival and prognostic factors in 155 patients. J Neurol Sci 223 2 (2004) 167-178
160. Grant R., Naylor B., Greenberg H.S., and Junck L. Clinical outcome in aggressively treated meningeal carcinomatosis. Arch Neurol 51 5 (1994) 457-461
161. Siegal T. Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy?. J Neurooncol 38 2-3 (1998) 151-157
162. Bleyer W.A., and Poplack D.G. Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Semin Oncol 12 2 (1985) 131-148
163. Frank J.A., Girton M., Dwyer A.J., Wright D.C., Cohen P.J., and Doppman J.L. Meningeal carcinomatosis in the VX2 rabbit tumor model: detection with Gd-DTPA-enhanced MR imaging. Radiology 167 3 (1988) 825-829
164. Blasberg R.G., Patlak C.S., and Shapiro W.R. Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration. Cancer Treat Rep 61 4 (1977) 633-641
165. Grossman S.A., Reinhard C.S., and Loats H.L. The intracerebral penetration of intraventricularly administered methotrexate: a quantitative autoradiographic study. J Neurooncol 7 4 (1989) 319-328
166. Morra E., Lazzarino M., Brusamolino E., et al. The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia. Clinical results in 46 patients. Cancer 72 2 (1993) 439-445
167. Tetef M.L., Margolin K.A., Doroshow J.H., et al. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol 46 1 (2000) 19-26
168. Boogerd W., Dorresteijn L.D., van Der Sande J.J., de Gast G.C., and Bruning P.F. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 55 1 (2000) 117-119
169. Baculi R.H., Suki S., Nisbett J., Leeds N., and Groves M. Meningeal carcinomatosis from breast carcinoma responsive to trastuzumab. J Clin Oncol 19 13 (2001) 3297-3298
170. Ohta M., Tokuda Y., Suzuki Y., et al. A case with HER2-overexpressing breast cancer completely responded to humanized anti-HER2 monoclonal antibody. Jpn J Clin Oncol 31 11 (2001) 553-556
171. Rogers L.R., Remer S.E., and Tejwani S. Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy. Neurooncol 6 1 (2004) 63-64
172. Giglio P., Tremont-Lukats I.W., and Groves M.D. Response of neoplastic meningitis from solid tumors to oral capecitabine. J Neurooncol 65 2 (2003) 167-172
173. Siegal T., Horowitz A., and Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg 83 6 (1995) 1029-1037
174. Siegal T. Toxicity of treatment for neoplastic meningitis. Curr Oncol Rep 5 1 (2003) 41-49
175. Geiser C.F., Bishop Y., Jaffe N., Furman L., Traggis D., and Frei III E. Adverse effects of intrathecal methotrexate in children with acute leukemia in remission. Blood 45 2 (1975) 189-195
176. Filley C.M., and Kleinschmidt-DeMasters B.K. Toxic leukoencephalopathy. N Engl J Med 345 6 (2001) 425-432
177. Bokstein F., Lossos A., and Siegal T. Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 82 9 (1998) 1756-1763
178. Crossen J.R., Garwood D., Glatstein E., and Neuwelt E.A. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 12 3 (1994) 627-642
179. Sheline G.E., Wara W.M., and Smith V. Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys 6 9 (1980) 1215-1228
180. Bleyer W.A. Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat Rep 65 S1 (1981) 89-98
181. Bleyer W.A., Nelson J.A., and Kamen B.A. Accumulation of methotrexate in systemic tissues after intrathecal administration. J Pediatr Hematol Oncol 19 6 (1997) 530-532
182. Mehta B.M., Glass J.P., and Shapiro W.R. Serum and cerebrospinal fluid distribution of 5-methyltetrahydrofolate after intravenous calcium leucovorin and intra-Ommaya methotrexate administration in patients with meningeal carcinomatosis. Cancer Res 43 1 (1983) 435-438
183. Stapleton S., and Blaney S. New agents for intrathecal administration. Cancer Invest 24 5 (2006) 528-534
184. Chamberlain M.C., Tsao-Wei D.D., and Groshen S. Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer 106 9 (2006) 2021-2027
185. Blaney S.M., Balis F.M., Berg S., et al. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol 23 7 (2005) 1555-1563
186. Blaney S.M., Boyett J., Friedman H., et al. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). J Clin Oncol 23 3 (2005) 525-531
187. Blaney S.M., Heideman R., Berg S., et al. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol 21 1 (2003) 143-147
188. Kochi M., Kuratsu J., Mihara Y., et al. Ventriculolumbar perfusion of 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosour ea hydrochloride. Neurosurgery 33 5 (1993) 817-823
189. Ushio Y., and Kochi M. Intrathecal perfusion chemotherapy with ACNU against subarachnoid dissemination of glioma in children. Int J Pediatr Hematol Oncol 5 1 (1998) 55-56
190. Ushio Y., Kochi M., Kitamura I., and Kuratsu J.I. Ventriculolumber perfusion of 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosour ea hydrochloride for subarachnoid dissemination of gliomas. J Neurooncol 38 2-3 (1998) 207-212
191. Chen Y.M., Chen M.C., Tsai C.M., and Perng R.P. Intrathecal gemcitabine chemotherapy for non-small cell lung cancer patients with meningeal carcinomatosis: a case report. Lung Cancer 40 1 (2003) 99-101
192. Sampson J.H., Archer G.E., Villavicencio A.T., et al. Treatment of neoplastic meningitis with intrathecal temozolomide. Clin Cancer Res 5 5
193. Friedman H.S., Archer G.E., McLendon R.E., et al. Intrathecal melphalan therapy of human neoplastic meningitis in athymic nude rats. Cancer Res 54 17 (1994) 4710-4714
194. Chamberlain M.C. A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer 94 10 (2002) 2675-2680
195. Mitchell M.S. Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J Clin Oncol 7 11 (1989) 1701-1709
196. Samlowski W.E., Park K.J., Galinsky R.E., Ward J.H., and Schumann G.B. Intrathecal administration of interleukin-2 for meningeal carcinomatosis due to malignant melanoma: sequential evaluation of intracranial pressure, cerebrospinal fluid cytology, and cytokine induction. J Immunother 13 1 (1993) 49-54
197. Herrlinger U., Weller M., and Schabet M. New aspects of immunotherapy of leptomeningeal metastasis. J Neurooncol 38 2-3 (1998) 233-239
198. Platini C., Long J., and Walter S. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 7 9 (2006) 778-780
199. Stemmler H.J., Schmitt M., Harbeck N., et al. Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 15 5 (2006) 1373-1377
200. Laufman L.R., and Forsthoefel K.F. Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer 2 3 (2001) 235
201. Schulz H., Pels H., Schmidt-Wolf I., Zeelen U., Germing U., and Engert A. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 89 6 (2004) 753-754
202. Herrlinger U., Schmidberger H., Buchholz R., Wehrmann M., Vallera D.A., and Schabet M. Intrathecal therapy of leptomeningeal CEM T-cell lymphoma in nude rats with anti-CD7 ricin toxin A chain immunotoxin. J Neurooncol 40 1 (1998) 1-9
203. Bigner D.D., Archer G.E., McLendon R.E., et al. Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis. Clin Cancer Res 1 12 (1995) 1545-1555
204. Hall W.A., Myklebust A., Godal A., Nesland J.M., and Fodstad O. In vivo efficacy of intrathecal transferrin-Pseudomonas exotoxin A immunotoxin against LOX melanoma. Neurosurgery 34 4 (1994) 649-655
205. Cokgor I., Akabani G., Friedman H.S., et al. Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab′)(2): a case study. Cancer 91 9 (2001) 1809-1813
206. Bigner D.D., Brown M., Coleman R.E., et al. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F(ab′)2: a preliminary report. J Neurooncol 24 1 (1995) 109-122
207. Kramer K., Cheung N.K., Humm J.L., et al. Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8. Med Pediatr Oncol 35 6 (2000) 716-718
208. Modak S., Kramer K., Gultekin S.H., Guo H.F., and Cheung N.K. Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res 61 10 (2001) 4048-4054
209. Aiken R.D. Neurologic complications of head and neck cancers. Semin Oncol 33 3 (2006) 348-351
210. Giglio P., Weinberg J.S., Forman A.D., Wolff R., and Groves M.D. Neoplastic meningitis in patients with adenocarcinoma of the gastrointestinal tract. Cancer 103 11 (2005) 2355-2362
211. Burstein H.J., Lieberman G., Slamon D.J., Winer E.P., and Klein P. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 16 11 (2005) 1772-1777
212. Batchelor T., and Loeffler J.S. Primary CNS lymphoma. J Clin Oncol 24 8 (2006) 1281-1288
213. Chamberlain M.C. Leptomeningeal metastases: a review of evaluation and treatment. J Neurooncol 37 3 (1998) 271-284